NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
FETZIMA (levomilnacipran hydrochloride) by AbbVie is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Approved for major depressive disorder (mdd) in adults (). First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FETZIMA (levomilnacipran hydrochloride) is an oral extended-release capsule approved in July 2013 by the FDA for treating Major Depressive Disorder (MDD) in adults. It is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by blocking the reuptake of serotonin and norepinephrine in the central nervous system, thereby potentiating their effects. As an SNRI, FETZIMA competes in the established antidepressant market alongside SSRIs, other SNRIs, and emerging mechanisms for MDD treatment.
$0.0BPart D
6.1 years to LOEMechanism of Action
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and…
Indications (1)
Career Relevance
FETZIMA supports a limited commercial infrastructure typical of a mature, secondary-position antidepressant brand, including brand managers, field representatives, and medical science liaisons focused on prescriber education. Success in this role requires deep knowledge of MDD treatment algorithms, competitive positioning against generics, and formulary navigation expertise. Currently, zero job openings are linked to this product, reflecting its stable but non-growth market position.
Worked on FETZIMA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.